GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Piotroski F-Score
中文

Alterity Therapeutics (Alterity Therapeutics) Piotroski F-Score : 0 (As of Apr. 24, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alterity Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Alterity Therapeutics's Piotroski F-Score or its related term are showing as below:

During the past 13 years, the highest Piotroski F-Score of Alterity Therapeutics was 2. The lowest was 0. And the median was 2.


Alterity Therapeutics Piotroski F-Score Historical Data

The historical data trend for Alterity Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Piotroski F-Score Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A - 1.00 1.00 -

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 - - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was 0 + -2.606 + 0 + 0.353 = $-2.25 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(29.067 + 0 + 22.526 + 0 + 18.334) / 5 = $23.309 Mil.
Total Assets at the begining of this year (Sep22) was $29.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.07 Mil.
Total Current Assets was $18.15 Mil.
Total Current Liabilities was $2.94 Mil.
Net Income was 0 + 0 + 0 + 0 = $0.00 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(25.677 + 0 + 32.139 + 0 + 29.067) / 5 = $28.961 Mil.
Total Assets at the begining of last year (Sep21) was $25.68 Mil.
Long-Term Debt & Capital Lease Obligation was $0.04 Mil.
Total Current Assets was $28.91 Mil.
Total Current Liabilities was $4.09 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alterity Therapeutics's current Net Income (TTM) was 0.00. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alterity Therapeutics's current Cash Flow from Operations (TTM) was -2.25. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=0/29.067
=0

ROA (Last Year)=Net Income/Total Assets (Sep21)
=0/25.677
=0

Alterity Therapeutics's return on assets of this year was 0. Alterity Therapeutics's return on assets of last year was 0. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Alterity Therapeutics's current Net Income (TTM) was 0.00. Alterity Therapeutics's current Cash Flow from Operations (TTM) was -2.25. ==> -2.25 <= 0.00 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0.069/23.309
=0.00296023

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=0.042/28.961
=0.00145023

Alterity Therapeutics's gearing of this year was 0.00296023. Alterity Therapeutics's gearing of last year was 0.00145023. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=18.154/2.941
=6.17273036

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=28.914/4.09
=7.06943765

Alterity Therapeutics's current ratio of this year was 6.17273036. Alterity Therapeutics's current ratio of last year was 7.06943765. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Alterity Therapeutics's number of shares in issue this year was 0. Alterity Therapeutics's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Alterity Therapeutics's gross margin of this year was . Alterity Therapeutics's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=0/29.067
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=0/25.677
=0

Alterity Therapeutics's asset turnover of this year was 0. Alterity Therapeutics's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+0+1+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alterity Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Alterity Therapeutics  (NAS:ATHE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Alterity Therapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics (Alterity Therapeutics) Headlines